ArticleFrontiers in cell and developmental biology2022
The Pan-Cancer Crosstalk Between the
Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- PRKN mediates the ubiquitination of SCAF8 to reduce the mRNA stability of KLF5 and its transcriptional activation of EFNA3 in colorectal cancer.Cellular & molecular biology letters · 2026Article
- Identification of two novel PATL2 variants and transcriptome sequencing reveals their role in oocyte maturation.Journal of ovarian research · 2026Article
- Single-cell epigenetic landscape, microenvironment interactions, and gene regulatory modules of non-functioning pituitary adenomas.Cell systems · 2026Article
- Ephrin-A4 ligand promotes gastric cancer cell epithelial-mesenchymal transition via the PI3K/AKT signaling pathway.Discover oncology · 2026Article
- ScRNA-Seq Deciphers an Autocrine EFNA1-EPHA1 Loop That Reprograms the Microenvironment in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Identification of EFNA3 as candidate prognosis marker and potential therapeutic target for adrenocortical carcinoma.Oncology letters · 2025Article
- A prognostic risk prediction model for gastric cancer based on the EFNA4 and ETS1 regulatory axis in tumor cells.Scientific reports · 2025Article
- EphA3/EFNA3 Reverse Signalling Promotes Epithelial-to-Mesenchymal Transition via ERK Pathway to Facilitate Colorectal Cancer Metastasis.Digestive diseases and sciences · 2025Article
- Article
- Exploring LAT-derived miRNAs as regulatory agents of EphrinA3 in glioblastoma multiforme.Biochemistry and biophysics reports · 2025Article
- EFNA4 deletion suppresses the migration, invasion, stemness, and angiogenesis of gastric cancer cells through the inactivation of Pygo2/Wnt signaling.Histology and histopathology · 2025Article
- Machine learning-random forest model was used to construct gene signature associated with cuproptosis to predict the prognosis of gastric cancer.Scientific reports · 2025Article
- Role of EFNAs in Shaping the Tumor Immune Microenvironment and Their Impact on Pancreatic Adenocarcinoma Prognosis.Cancer management and research · 2025Article
- Integrative single-cell and exosomal multi-omics uncovers SCNN1A and EFNA1 as non-invasive biomarkers and drivers of ovarian cancer metastasis.Frontiers in immunology · 2025Article
- TheJournal of gastrointestinal oncology · 2024Article
- Article
- EFHD1 expression is correlated with tumor-infiltrating neutrophils and predicts prognosis in gastric cancer.Heliyon · 2023Article
- Single-cell RNA sequencing reveals the heterogeneity and microenvironment in one adenoid cystic carcinoma sample.Functional & integrative genomics · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.